EMA/538918/2012

European Medicines Agency decision

P/0206/2012

of 17 September 2012

on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir (phosphate) (Tamiflu), (EMEA-000365-PIP01-08-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision
P/0206/2012

of 17 September 2012

on the acceptance of a modification of an agreed paediatric investigation plan for oseltamivir (phosphate) (Tamiflu), (EMEA-000365-PIP01-08-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/192/2009 issued on 2 October 2009, and the decision P/29/2011 issued on 28 January 2011,

Having regard to the application submitted by Roche Registration Ltd on 20 April 2012 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 7 September 2012, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given, following a re-examination procedure of the Paediatric Committee's opinion according to Article 25(3) Regulation (EC) No 1901/2006, an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the granting of changes to the agreed paediatric investigation plan.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for oseltamivir (phosphate) (Tamiflu), hard capsules, powder for oral suspension, oral use, are hereby accepted in the scope set out in the opinion

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Roche Registration Ltd, 6 Falcon Way, Shire Park, AL7 1TW, Welwyn Garden City, United Kingdom

Done at London, 17 September 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/534316/2012

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan (after re-examination)

EMEA-000365-PIP01-08-M04

Scope of the application

Active substance(s):

Oseltamivir (phosphate)

Invented name:

Tamiflu

Condition(s):

Treatment and prevention of influenza

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Hard capsules

Powder for oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Roche Registration Ltd

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Roche Registration Ltd submitted to the European Medicines Agency on 20 April 2012 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/192/2009 issued on 2 October 2009, and the decision P/29/2011 issued on 28 January 2011. The application for modification proposed changes to the agreed paediatric investigation plan.

An Opinion was adopted by the Paediatric Committee on 6 July 2012 for the above mentioned product. Roche Registration Ltd received the Paediatric Committee Opinion on 12 July 2012.

On 13 August 2012 Roche Registration Ltd submitted to the European Medicines Agency a written request including detailed grounds for a re-examination of the Opinion.

The re-examination procedure started on 14 August 2012.

Scope of the modification

Changes to some measures of the Paediatric Investigation Plan have been requested.

Final Opinion

1. The Paediatric Committee, having assessed the detailed grounds for re-examination, in accordance with Article 25(3) of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

1.1. to maintain its opinion and to agree to the changes regarding the measures of the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 7 September 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: Treatment and prevention of Influenza

2.1.1. Indication(s) targeted by the PIP

Treatment and prevention of influenza in healthy and immunocompromised patients from birth to less than 18 years of age.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Hard capsules for oral use.

Powder for oral suspension for oral use.

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	4	Study 1: Open-label, non-randomised, PK / PD and safety trial to evaluate oseltamivir in children less than 24 months of age with confirmed influenza infection. Study 2: Randomized, double-blind, multi-centre, stratified trial to evaluate efficacy, safety, tolerability and resistance of oseltamivir conventional and high dose for the treatment of in immunocompromised paediatric patients from 1 year to less than 18 years of age (and in adults) with influenza. Study 3: To simulate multi-dose administration of oseltamivir in immunocompromised children from birth to less than 18 year of age for treatment and prophylaxis of influenza. Study 4: Open label, non-randomized, multiple dose PK/PD and safety trial of oseltamivir in the treatment of infants from birth to less than 12 months of age with confirmed influenza infection.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2014
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Influenza

   Authorised indications:

   Treatment of influenza

- In patients one year of age and older who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. This indication is based on clinical studies of naturally occurring influenza in which the predominant infection was influenza A (see section 5.1).
- Tamiflu is indicated for the treatment of infants below 12 months of age during a pandemic influenza outbreak (see section 5.2).

   Prevention of influenza

- Post-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.
- The appropriate use of Tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g., in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older.

   Tamiflu is indicated for post-exposure prevention of influenza in infants below 12 months of age during a pandemic influenza outbreak (see section 5.2).Authorised indication:

EU Number	**Invented name**	**Strength**	**Pharmaceutical Form**	**Route of Administration**	**Packaging**	**Content (concentration)**	**Package size**
EU/1/02/222/003	Tamiflu	30 mg	Capsule, hard	Oral use	blister (PVC/PE/PVDC/alu)		10 capsules
EU/1/02/222/004	Tamiflu	45 mg	Capsule, hard	Oral use	blister (PVC/PE/PVDC/alu)		10 capsules
EU/1/02/222/001	Tamiflu	75 mg	Capsule, hard	Oral use	blister (PVC/PE/PVDC/alu)		10 capsules
EU/1/02/222/002	Tamiflu	12 mg/ml	Powder for oral suspension	Oral use	bottle (glass)	30 g	1 bottle